Side-by-Side Comparison
AOD-9604 vs Semaglutide: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how AOD-9604 and Semaglutide differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
AOD-9604
L2Also: Advanced Obesity Drug 9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.
Also: Ozempic, Wegovy, Rybelsus
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Side-by-side comparison
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Primary mechanism | Lipolytic GH Fragment Activity | GLP-1 Receptor Agonism |
| FDA status | Research Only | FDA Approved |
| Evidence level | Preclinical Evidence | FDA Approved |
| Human trials | Yes (1+ indexed) | Yes (100+ indexed) |
| Studies indexed | 23 total (2 human, 14 animal) | 630 total (380 human, 120 animal) |
| Primary uses researched | Fat metabolism, Weight loss | Weight management, Type 2 diabetes, Cardiovascular risk reduction |
| Administration routes | oral, subcutaneous | oral, subcutaneous |
| Molecular weight | 1815.08 Da | 4113.58 Da |
| Amino acids | 16 | 31 |
| Category | weight loss | weight loss |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. AOD-9604 acts primarily through lipolytic gh fragment activity, while Semaglutide acts primarily through glp-1 receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. AOD-9604 is classified as research only; Semaglutide is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Semaglutide sits at a higher evidence level (L5) than AOD-9604 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on AOD-9604 has concentrated on fat metabolism, weight loss. Research on Semaglutide has concentrated on weight management, type 2 diabetes, cardiovascular risk reduction. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Documented effects | 4 total | 14 total |
| Serious events | 0 | 1 |
| Common events | 1 | 5 |
| Black box warning | No | Yes |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 3 flagged |
| Most common event | Injection site reactions | Nausea |
Strengths & limitations
AOD-9604
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Semaglutide
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (100+ indexed)
- Large indexed research base (630 studies)
Limitations
- Carries an FDA black box warning
Representative studies
AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Stier H, et al. · Journal of Obesity & Weight Loss Therapy (2013)
AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial.
AOD 9604 Promotes Cartilage Proliferation and Type II Collagen Synthesis in Osteoarthritic Chondrocytes
Wu X, Brown L, Kasran A, et al. · International Journal of Obesity (2007)
AOD 9604 increased type II collagen synthesis by 180% and cartilage proteoglycan content by 156% in human OA chondrocytes.
PubMed 17387518Semaglutide
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021)
Semaglutide 2.4mg weekly resulted in 14.9% mean body weight reduction, with 86.4% achieving ≥5% and 50.5% achieving ≥15% weight loss.
PubMed 33567185Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Garvey WT, Batterham RL, Bhatt DL, et al. · Nature Medicine (2022)
Semaglutide 2.4mg maintained 15.2% weight loss at 2 years, demonstrating durable efficacy with continued treatment.
PubMed 36356234Frequently asked
What is the main difference between AOD-9604 and Semaglutide?
AOD-9604 is a modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full gh. Its primary mechanism is lipolytic gh fragment activity. Semaglutide is an fda-approved glp-1 receptor agonist used for type 2 diabetes and chronic weight management. Its primary mechanism is glp-1 receptor agonism. The two differ in regulatory status (Research Only vs FDA Approved), strength of evidence (L2 vs L5), and the primary conditions for which each is researched.
Is AOD-9604 or Semaglutide FDA approved?
AOD-9604: Not FDA-approved. Has GRAS (Generally Recognized as Safe) status as a food additive only. Not approved as a drug. Semaglutide: FDA-approved GLP-1 receptor agonist. Ozempic approved for type 2 diabetes (2017). Wegovy approved for chronic weight management (2021) and cardiovascular risk reduction (2024).
How does the evidence base compare?
AOD-9604 has 23 indexed studies (2 human, 14 animal) and is rated Preclinical Evidence. Semaglutide has 630 indexed studies (380 human, 120 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can AOD-9604 and Semaglutide be compared directly?
Yes — both compounds share the weight loss category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are AOD-9604 and Semaglutide commonly stacked together?
There is no widely documented stacking protocol combining AOD-9604 and Semaglutide in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, AOD-9604 or Semaglutide?
AOD-9604 has 4 documented side effects (0 serious). Semaglutide has 14 documented side effects (1 serious, including a black box warning). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are AOD-9604 and Semaglutide administered?
Both are administered via oral or subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, AOD-9604 or Semaglutide?
"Better" depends on the therapeutic goal, regulatory context, and individual response. AOD-9604 is most researched for fat metabolism and weight loss; Semaglutide is most researched for weight management and type 2 diabetes. FDA status also matters: Research Only for AOD-9604 vs FDA Approved for Semaglutide. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
AOD-9604 →
Full profile
Semaglutide →